ONC Share Price

Open 0.50 Change Price %
High 0.51 1 Day 0.01 2.00
Low 0.48 1 Week 0.02 4.08
Close 0.51 1 Month 0.03 6.25
Volume 91514 1 Year 0.15 41.67
52 Week High 1.13
52 Week Low 0.19
ONC Important Levels
Resistance 2 0.54
Resistance 1 0.53
Pivot 0.50
Support 1 0.49
Support 2 0.48
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
SC 60.83 -0.44%
PRE 0.64 0.00%
PRE 0.64 0.00%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
ORA 1.73 13.07%
ORA 1.73 13.07%
More..
TSE Canada Top Losers Stocks
COM 3.26 -34.67%
COM 3.26 -34.67%
COM 3.26 -34.67%
COM 3.26 -34.67%
HE 0.02 -33.33%
HE 0.02 -33.33%
TPL 0.02 -33.33%
TPL 0.02 -33.33%
GBV 0.46 -24.59%
CQE 0.14 -12.50%
More..

Oncolytics Biotech Inc (TSE: ONC)

ONC Technical Analysis 1.5
As on 21st Aug 2017 ONC Share Price closed @ 0.51 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.46 & Sell for SHORT-TERM with Stoploss of 0.51 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONC Target for August
1st Target up-side 0.58
2nd Target up-side 0.63
3rd Target up-side 0.68
1st Target down-side 0.42
2nd Target down-side 0.37
3rd Target down-side 0.32
ONC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncolyticsbiotech.com
ONC Address
ONC
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
Phone: 403-670-7377
Fax: 403-283-0858
ONC Latest News
Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results   PR Newswire (press release)   - 03rd Aug 17
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual ...   PR Newswire (press release)   - 01st Aug 17
BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA   Reuters   - 26th Jul 17
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with ...   PR Newswire (press release)   - 26th Jul 17
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of ...   PR Newswire (press release)   - 29th Jun 17
Oncolytics Biotech Prices Public Offering of Units   MarketWatch   - 24th May 17
Finally, Some Good News For Oncolytics   Seeking Alpha   - 03rd Apr 17
Oncolytics Biotech® Inc. Announces Appointment of New Chief Medical Officer   PR Newswire (press release)   - 10th Nov 16
Where Can Oncolytics Go After Dismal ASCO Results?   Seeking Alpha   - 20th May 16
On the Reversal: Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)   MicroCap Daily   - 10th Feb 15
Interactive Technical Analysis Chart Oncolytics Biotech Inc ( ONC TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncolytics Biotech Inc
ONC Business Profile
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.